TECregen
TECregen is a Basel-based, privately held biotechnology company founded in 2023 that develops thymopoietic biologics to rejuvenate the thymus, restore thymic epithelial cells, and replenish T-cell function for applications in immunology, oncology, and rare immune disorders.
- Company typePrivate
- Founded2023
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What TECregen does
TECregen is a privately held, Basel-based biotechnology company founded in 2023 that develops thymus-rejuvenating biologics aimed at restoring adaptive immune function. The company's central premise is that age- and therapy-related immune decline can be addressed at its biological root by regenerating thymic tissue rather than treating downstream symptoms. TECregen operates a thymopoietic biologics platform — a pipeline of biologic candidates engineered to restore thymic epithelial cells and replenish T-cell populations, with stated applications in immune recovery post-therapy, cancer immune surveillance, and rare immune disorders across the immunology, oncology, and rare disease verticals.
The platform is positioned by the company as a first-mover in thymus regeneration, distinguishing its mechanism from symptomatic immunotherapies. TECregen is currently pre-clinical or early clinical, with no disclosed commercial product, no publicly available pricing, and no identified customers in the input data. As of January 2026, the company had 1-10 employees and was operating with a single lead investor consortium. The technology and product detail available to investors is high-level: the source material describes the platform's mechanism and target indications but does not enumerate specific candidate molecules, clinical trial readouts, or regulatory milestones.
TECregen's business model is that of a venture-backed clinical-stage biotech: it has no revenue-generating operations, and its runway is funded by equity capital rather than product sales or licensing income. In January 2026 the company closed a CHF 10 million (USD 12.6 million) seed round led by Boehringer Ingelheim Venture Fund, with participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds, JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank. Concurrent with the financing, the company appointed Dr. Bo Rode Hansen (former CEO of Scandion Oncology; ex-Roche/Santaris) as Chairman and Dr. Klaas P. Zuideveld (20+ years pharma/biotech drug development experience) as CEO, explicitly to drive the transition into clinical development. Distribution, marketing channels, and pricing models are not applicable at this stage and were not disclosed in the source material.
TECregen firmographics
Firmographics- Name
- TECregen
- Website
- https://tecregen.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- TECregen is a Basel-based, privately held biotechnology company founded in 2023 that develops thymopoietic biologics to rejuvenate the thymus, restore thymic epithelial cells, and replenish T-cell function for applications in immunology, oncology, and rare immune disorders.
- Ownership category
- akta.pro rank
TECregen industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- akta.pro industry
- Stem Cell–Based Regenerative TherapiesRecombinant Protein Therapeutics (enzymes, hormones, growth factors)Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)CAR-T & TCR-T TherapiesRegenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Keywords
Where TECregen is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
TECregen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
TECregen product offering
Product offeringCore offering
TECregen develops a pipeline of thymopoietic biologics designed to restore thymic epithelial cells and replenish T-cells. The platform targets immune recovery post-therapy, cancer immune surveillance, and rare diseases involving impaired immune responses, with the goal of rejuvenating the thymus organ to address the root cause of immune decline.
Product overview
TECregen is a single-product biotech company developing a thymopoietic biologics platform focused on thymus rejuvenation. The platform consists of a pipeline of biologics designed to restore thymic epithelial cells and replenish T-cells for applications in immunology, oncology, and rare diseases involving impaired immune responses.
Differentiator
Problem solved
Functional benefit
Products and services
- Thymopoietic Biologics Platform A biologics platform designed to restore thymic epithelial cells and improve T-cell immune function through thymus rejuvenation. It targets applications including immune recovery post-therapy and cancer immune surveillance for patients with impaired immune responses.
Companies that use TECregen
Customer profileSegments3 records
Ideal customer profiles1 record
TECregen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
TECregen partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights4 records
TECregen competitors and assessment
Company assessmentEmerging players
- Turn Biotechnologies: Turn Biotechnologies develops an mRNA-based platform for cellular reprogramming aimed at restoring function in aged or damaged cells, with applications in immune and inflammatory diseases. Comparable to TECregen as a rejuvenation-focused biologics company, though Turn uses a reprogramming-based mechanism rather than thymus-targeted biologics.
- Celdara Medical: Celdara Medical is a regenerative-medicine-focused biotech that develops cell-based and biologic therapies for immune and inflammatory disorders. It is comparable to TECregen as a small-cap biotech operating in regenerative immunology with multiple asset programs.
- AgeX Therapeutics: AgeX Therapeutics is a regenerative medicine company focused on age-related degenerative diseases, including cellular rejuvenation and immune-system aging. It is comparable to TECregen in its focus on using biologics and cells to counter age-related immune decline, though via different platforms.
- Cellevate: Cellevate is a Swedish biotech developing nanocellulose-based platforms for cell culture and cell therapy applications, including regenerative medicine use cases. It is comparable as a European early-stage regenerative-medicine biotech operating in adjacent immune and tissue-engineering spaces to TECregen.
- Calimmune: Calimmune developed cell and gene therapy approaches aimed at modifying immune cells, including for immune reconstitution. It is comparable to TECregen in its focus on immune system restoration, although via an ex vivo cell/gene-therapy modality rather than in vivo thymus rejuvenation.
- Cue Biopharma: Cue Biopharma develops engineered protein biologics designed to selectively modulate T-cell activity for oncology and autoimmune disease. It is comparable to TECregen as a protein-biologics platform targeting T-cell–mediated immunity, though it focuses on modulating existing T cells rather than regenerating the thymus that produces them.
Broad incumbents
- Altos Labs: Altos Labs is a well-capitalized cellular rejuvenation company pursuing biological reprogramming to restore cellular function across tissues, including the immune system. It is comparable as a broad incumbent in rejuvenation biology that addresses similar downstream indications to TECregen, but at vastly greater scale and capital.
- Revvity (formerly BioLegend cell-therapy reagents) / Regeneron immune-reconstitution research partners: Regeneron is a large biopharmaceutical company with active programs in immune modulation, including antibody-based approaches that intersect with immune-restoration biology. It is comparable as a broad incumbent with adjacent capabilities that could compete with or partner around TECregen's thymus-regeneration thesis.
Direct peers
- Lygenesis: Lygenesis is developing a technology to regenerate organs — including the thymus — by re-implanting patients' own hepatocytes into lymph nodes. Comparable to TECregen because it pursues in vivo thymus/immune organ regeneration as a therapeutic modality, although via a cell-based rather than biologics approach.
- Intervene Immune: Intervene Immune is a clinical-stage biotech developing therapeutics to restore thymic function and rejuvenate the immune system. It is the closest direct competitor to TECregen, addressing the same underlying biology (thymus regeneration) for immune restoration in aging and disease.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
TECregen financial estimates
Financial estimateRevenue estimate
Valuation estimate
TECregen leadership team
Management profileNumber of profiles
Profiles2 records
TECregen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TECregen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TECregen
What does TECregen do?
TECregen develops a pipeline of thymopoietic biologics designed to restore thymic epithelial cells and replenish T-cells. The platform targets immune recovery post-therapy, cancer immune surveillance, and rare diseases involving impaired immune responses, with the goal of rejuvenating the thymus organ to address the root cause of immune decline.
Is TECregen a public or private company?
TECregen is a private company. It is classified as venture growth investor backed and is currently operating.
When was TECregen founded?
TECregen was founded in 2023. It employs 1 to 10 people.
Where is TECregen based?
TECregen is headquartered in Basel, Switzerland, in the Europe region.
Who are TECregen's main competitors?
Emerging players on record are Turn Biotechnologies, Celdara Medical, AgeX Therapeutics, Cellevate, Calimmune and Cue Biopharma. Broad incumbents are Altos Labs and Revvity (formerly BioLegend cell-therapy reagents) / Regeneron immune-reconstitution research partners. Direct peers are Lygenesis and Intervene Immune.
Does TECregen have an API?
No public API is recorded for TECregen.
What industry is TECregen in?
TECregen's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414.